Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-issues-complete-response-letter-for-byondis-vic-trastuzumab-duocarmazine-301824573.html
https://www.prnewswire.com/news-releases/byondis-initiates-phase-i-study-of-next-generation-antibody-drug-conjugate-byon3521-301611571.html
https://www.prnewswire.com/news-releases/ema-validates-marketing-authorization-application-for-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer-301587559.html
https://www.prnewswire.com/news-releases/fda-accepts-byondis-biologics-license-application-for-vic--trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer-301584658.html
https://www.pharmatimes.com/news/byondis_and_medac_link_up_to_commercialise_trastuzumab_duocarmazine_1447848
https://www.contractpharma.com/contents/view_breaking-news/2022-05-03/byondis-partners-with-medac-to-commercialize-antibody-drug-conjugate/?widget=listSection
https://www.prnewswire.com/news-releases/byondis-esmo-late-breaking-presentation-confirms-adc-vic--trastuzumab-duocarmazine-syd985-superior-to-physicians-choice-in-pre-treated-locally-advanced-or-metastatic-her2-positive-breast-cancer-301379760.html
https://www.prnewswire.com/news-releases/byondis-appoints-timo-van-den-berg-as-senior-director-immuno-oncology-rd-301333957.html
http://www.pharmafile.com/news/579692/phase-iii-breast-cancer-trial-meets-primary-endpoint